And as demand continues to grow, what factors will determine whether patients can start and adhere to treatment long term
Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
They reduce the level of fat in the liver, which is associated with improved health and reduced risk of cardiac or glycemic abnormalities
FDA-Approved Versions and Supply Shortages The demand for Semaglutide for weight loss and diabetes management has skyrocketed, leading to shortages of FDA-approved versions of the medication
Medications are shipped via FedEx
And trust me, you dont want to mess around with expired biologics